Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer? Comment

被引：2
|
作者：
Sepesi, Boris [1 ]
Cascone, Tina [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 06期
关键词：
SINGLE-ARM; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER;
D O I：
10.1016/S1470-2045(21)00261-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：744 / 746
页数：3
相关论文
共 50 条
  • [31] Radiation Therapy in Non-Small-Cell Lung Cancer
    Dohopolski, Michael
    Gottumukkala, Sujana
    Gomez, Daniel
    Iyengar, Puneeth
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2021, 11 (10):
  • [32] Individualized therapy of non-small-cell lung cancer
    Rosell, R
    LUNG CANCER, 2004, 45 : S19 - S19
  • [33] Vaccine therapy in non-small-cell lung cancer
    Albright C.
    Garst J.
    Current Oncology Reports, 2007, 9 (4) : 241 - 246
  • [34] Maintenance therapy in non-small-cell lung cancer
    Stinchcombe, Thomas E.
    West, Howard L.
    LANCET, 2009, 374 (9699): : 1398 - 1400
  • [35] Targeted therapy in non-small-cell lung cancer
    Herbst, RS
    ONCOLOGY-NEW YORK, 2002, 16 (09): : 19 - 24
  • [36] Vaccination therapy for non-small-cell lung cancer
    Cuppens, Kristof
    Vansteenkiste, Johan
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (02) : 165 - 170
  • [37] Trimodality therapy for non-small-cell lung cancer
    Roberts, JR
    ONCOLOGY-NEW YORK, 1999, 13 (10): : 101 - 106
  • [38] Maintenance therapy for non-small-cell lung cancer
    Belani, Chandra P.
    Liao, Jason
    LANCET, 2010, 375 (9711): : 281 - 282
  • [39] Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART Comment
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk K. M.
    LANCET ONCOLOGY, 2022, 23 (01): : 8 - 9
  • [40] Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer
    Isaacs, James
    Stinchcombe, Thomas E.
    DRUGS, 2022, 82 (08) : 855 - 863
12345